bioMérieux S.A. (BIM.PA)
Makes diagnostic tests that identify infections and bacteria from patient samples
74.95+0.06%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-39.6%
The outlook
bioMérieux is trading near the lower end of its 52-week range, with analyst consensus leaning slightly toward Hold across 13 coverage sources. The average price target sits about 9% above the current level, though the stock shows mixed momentum against its moving averages. A trailing P/E of 22.4 reflects moderate valuation relative to recent earnings.
What’s behind the score
Analyst consensusHold — 2.6 avg of 13 analysts
Price trendMixed vs its moving averages
52-week range15% of the way from its 52-week low to high
Price targetAvg target +9% vs current price
Analyst price target
~12-month · 13 analysts81.35average target+8.5% vs now
Now 74.95
Low 64.00High 105.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$8.84B
52-wk high
128.30
52-wk low
65.60
50-day avg
70.62
200-day avg
91.37
Trailing P/E
22.4